Bukwang Pharmaceutical and Novartis Venture Fund were among the latest investors in the developer of T-cell therapies for liquid and solid cancers.

US-based cancer treatment developer ImmPact Bio picked up $111m in a series B round on Thursday from investors including pharmaceutical firms Bukwang Pharmaceutical and Novartis.

VenBio Partners, Foresite Capital and Decheng Capital co-led the round, which included Surveyor Capital, OrbiMed and RM Global Partners (RMGP). Novartis took place through its corporate venturing vehicle, Novartis Venture Fund.

ImmPact Bio is working on chimeric antigen receptor (CAR) T-cell therapies both for haematological malignancies and solid tumours using the research conducted at University of…

Subscribe to go deeper

GCV subscribers get access to all our proprietary data and deep-dive articles, as well as the global directory of CVC investors.



Not sure if you have a subscription?
Thierry Heles

Thierry Heles is editor-at-large of Global University Venturing and Global Corporate Venturing, and host of the Beyond the Breakthrough podcast.
Email LinkedIn